Case closed: Novartis, government found no merit in allegations in Turkey

Novartis HQ

Novartis ($NVS) has acknowledged that employees in South Korea may have been involved in some rebate shenanigans. But it says an investigation of similar accusations in Turkey uncovered no problems. Now, Novartis considers the matter closed.

In April, a prosecutor in Turkey was reported to have opened an investigation after receiving a copy of an email sent by an anonymous whistleblower to Novartis CEO Joe Jimenez and a board member saying the unit there paid consultants $290,000 in 2013 and 2014 to win about $85 million in business from government hospitals.

But in an email to Reuters today, the Swiss drugmaker said that it was unaware of any government authority in Turkey investigating the company and that the allegations had long ago been vetted and discredited.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

"Based on thorough internal and external counsel investigations we have concluded that all recent publicly and anonymously reported allegations relating to Novartis Turkey are unsubstantiated. We now consider this matter closed," it told the news service.

When reports surfaced in the spring that a prosecutor in Turkey had launched an investigation into the email, the drugmaker explained it had looked into the allegations way back in 2013 and 2014, collected up the info and shared it with authorities in Turkey, as well as the U.S. Securities and Exchange Commission. It said that upon review, the Republic of Turkey Ministry of Labor and Social Security was satisfied and took no action.

The matter is not so cut and dry in South Korea. In that case, prosecutors want the government to suspend the company’s operations there after they indicted a half-dozen executives for issuing improper rebates.

Novartis quickly acknowledged that "some associates supported travel to overseas congresses for some healthcare practitioners" acting in a way that didn't comply with South Korea’s self-regulation standards and violated the company’s own policies. It said it was putting a remediation plan in place there.

But it was adamant in an emailed response that the bad players acted on their own: “We reject the implication that the alleged conduct was sanctioned by the most senior management of Novartis Korea. We will take time to review the details of the indictment thoroughly and consider our next steps.”

Novartis has had to face an interruption of business in an entire county before. Last spring, Japan suspended Novartis' operations in the country for 15 days for failing to properly report drug side effects. Novartis was the first drugmaker to receive that kind of punishment for a lapse in side effects reporting.

- here’s the Reuters story  

Related Articles: 
Novartis: Turkish ministry couldn't substantiate bribery claim 
Novartis faces legal action in Korea after exec indictments, including possible suspension 
South Korea prosecutors indict Novartis execs on drug sale rebate charges 
Prosecutors raid Novartis South Korea in kickbacks probe

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.